QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 sutro-biopharma-reveals-an-organizational-restructuring-to-prioritize-the-advancement-of-its-three-adc-programs-and-research-and-development-collaborations-the-restructuring-is-expected-to-extend-the-companys-runway-into-at-least-mid-2027--restructuring-to-result-in-workforce-reduction-of-one-third-of-employees-co-on-track-to-advance-stro-004-into-clinic-this-year-with-initial-data-expected-in-2026

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc.

 wells-fargo-maintains-equal-weight-on-sutro-biopharma-lowers-price-target-to-3

Wells Fargo analyst Derek Archila maintains Sutro Biopharma (NASDAQ:STRO) with a Equal-Weight and lowers the price target fr...

 sutro-biopharma-q2-eps-014-beats-045-estimate-sales-6374m-beat-1435m-estimate

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.4...

 sutro-biopharma-partners-with-fda-to-advance-standards-and-analytics-for-antibody-drug-conjugates-using-xpresscf-technology

- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format ant...

 piper-sandler-upgrades-sutro-biopharma-to-overweight-maintains-price-target-to-2

Piper Sandler analyst Edward Tenthoff upgrades Sutro Biopharma (NASDAQ:STRO) from Neutral to Overweight and maintains the pr...

 b-of-a-securities-maintains-underperform-on-sutro-biopharma-lowers-price-target-to-08

B of A Securities analyst Tazeen Ahmad maintains Sutro Biopharma (NASDAQ:STRO) with a Underperform and lowers the price targ...

 sutro-biopharma-q1-eps-091-misses-071-estimate-sales-1740m-beat-1161m-estimate

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0...

 hc-wainwright--co-reiterates-neutral-on-sutro-biopharma-maintains-2-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Sutro Biopharma (NASDAQ:STRO) with a Neutral and maintains $2 pr...

 sutro-biopharma-announces-poster-presentations-to-highlight-its-next-generation-exatecan-and-dual-payload-adc-programs-at-upcoming-american-association-for-cancer-research-april-25-30-in-chicago-illinois

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antib...

 hc-wainwright--co-downgrades-sutro-biopharma-to-neutral-lowers-price-target-to-2

HC Wainwright & Co. analyst Andrew Fein downgrades Sutro Biopharma (NASDAQ:STRO) from Buy to Neutral and lowers the pric...

 reported-saturday-sutro-highlights-late-breaking-refrme-o1-data-demonstrating-32-orr-and-96-dcr-with-optimized-luvelta-dosing-in-proc-patients

Late-Breaking Oral Presentation Highlights:At the selected optimized dose (5.2 mg/kg), luvelta achieved an ORR of 32%1 and a di...

 penny-stock-sutro-biopharma-cuts-costs-refocuses-pipeline

Sutro Biopharma reported $62 million in 2024 revenue, down from $153.7 million in 2023, and announced a pipeline restructuring.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION